HL-301

N/A

Report date: 2024/06/14 16:12:49
NME

Base Information

Drug NameHL-301
Drug Alias NameHL-301
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnti-T cell immunoglobulin and ITIM domainsAnti-Programmed death-ligand 1
TargetsT cell immunoglobulin and ITIM domainsProgrammed death-ligand 1
Therapy Area/IndicationsAcute BronchitisPulmonary Disease, Chronic ObstructiveRadiation Pneumonitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute BronchitisPulmonary Disease, Chronic Obstructive
Inactive IndicationsRadiation PneumonitisLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A